Bill Szablewski
Head of Capital Markets and Investor RelationsViatris
PharmaceuticalsView Profile →Senior Vice President, Investor Relations and Strategic Analysis · Regeneron Pharmaceuticals
Ryan Crowe is senior vice president of investor relations and strategic analysis at Regeneron Pharmaceuticals. He joined in 2022 after investor relations work at Myovant Sciences and finance-related responsibilities at Pfizer. His remit combines communication with investors and analysis supporting pipeline and commercial strategy.
Last reviewed: Oct 21, 2026
Senior Vice President, Investor Relations and Strategic Analysis Regeneron Pharmaceuticals
Last Reviewed: October 21, 2026
Ryan Crowe is senior vice president of investor relations and strategic analysis at Regeneron Pharmaceuticals. He joined in 2022 after investor relations work at Myovant Sciences and finance-related responsibilities at Pfizer. His remit combines communication with investors and analysis supporting pipeline and commercial strategy.
Crowe developed his career across corporate tax and investor relations at Pfizer, holding positions of increasing responsibility. He subsequently served as vice president of Investor Relations at Myovant Sciences before joining Regeneron in 2022.
At Regeneron, he leads Investor Relations and Strategic Analysis. One part of the role involves communicating the company’s business, scientific opportunities and value drivers to the investment community. The other leads a strategic analysis team informing the company’s pipeline and commercial priorities.
These responsibilities connect external financial communication with internal business analysis. His earlier experience in tax and investor relations provides a finance background for discussing a research-driven company with investors. The current company biography identifies both functions within his senior vice president position, rather than treating strategic analysis as a separate appointment.
Crowe earned a BS in commerce and engineering from Drexel University and an MBA from New York University’s Stern School of Business.